8 December, 2021 by The TZ Newswire Staff Comments Off on Analysis of Top 100 Cryptocurrencies (8 Dec 2021)
Analysis of Top 100 Cryptocurrencies (8 Dec 2021)
8 December, 2021 by The TZ Newswire Staff Comments Off on Market Extra: ‘Proceed with caution’: here’s what Wall Street analysts see for the U.S. stock market in 2022
Market Extra: ‘Proceed with caution’: here’s what Wall Street analysts see for the U.S. stock market in 2022
The recent spike in market volatility may herald a bumpier U.S.
8 December, 2021 by The TZ Newswire Staff Comments Off on Egon Von Greyerz – Misery Or Fortune: The Choice Is Yours
Egon Von Greyerz – Misery Or Fortune: The Choice Is Yours
8 December, 2021 by The TZ Newswire Staff Comments Off on Better Buy: Solana vs. Ethereum
Better Buy: Solana vs. Ethereum
Ethereum (CRYPTO: ETH) and Solana (CRYPTO: SOL) are both making headlines in the world of cryptocurrency. They’re growing in leaps and bounds when it comes to hosting projects on their blockchains and attracting investors to their coins. But their stories are a bit different. Ethereum arrived early on the crypto scene — back in 2015. While Solana launched in 2020. Now, the question is which is the best buy today — the more established player or the new kid on the block?
Image source: Getty Images.
8 December, 2021 by The TZ Newswire Staff Comments Off on Will ‘The Great Resignation’ Slow Down Anytime Soon?
Will ‘The Great Resignation’ Slow Down Anytime Soon?
If you’ve been paying attention to the monthly reports from the U.S. Bureau of Labor Statistics, you might have noticed that workers are still quitting their jobs in high numbers, even as the pandemic and inflation continue.
In this segment of Backstage Pass, recorded on Nov. 5, Fool contributors Toby Bordelon and Rachel Warren discuss the trajectory of The Great Resignation.
8 December, 2021 by The TZ Newswire Staff Comments Off on Affimed Initiates Patient Recruitment for a Phase 1/2a Trial of Innate Cell Engager AFM24 in Combination with Roche’s Anti-PD-L1 Checkpoint Inhibitor Atezolizumab
Affimed Initiates Patient Recruitment for a Phase 1/2a Trial of Innate Cell Engager AFM24 in Combination with Roche’s Anti-PD-L1 Checkpoint Inhibitor Atezolizumab
HEIDELBERG, Germany, Dec. 08, 2021 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD) a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today the initiation of patient recruitment for the open-label, multi-center phase 1/2a study evaluating the safety, tolerability, pharmacokinetics and efficacy of the innate cell engager (ICE®) AFM24 in combination with Roche’s atezolizumab, an anti-PD-L1 checkpoint inhibitor.
8 December, 2021 by The TZ Newswire Staff Comments Off on GZ6G Technologies Integrates Smart City and Smart Venue Cybersecurity Through Green Zebra Networks, as Cyber Attacks Run Rampant Nationwide
GZ6G Technologies Integrates Smart City and Smart Venue Cybersecurity Through Green Zebra Networks, as Cyber Attacks Run Rampant Nationwide
LAS VEGAS, NV, Dec. 08, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — GZ6G Technologies Corp.